Yeongyang

This research aims to gain approval in Korea for camrelizumab SHR-1210, a drug already approved in China, for treating patients with advanced or metastatic non-squamous non-small cell lung cancer NSCLC that is EGFRALK wild-type. The study focuses on patients with Stage IIIB-IV NSCLC to confirm camrelizumabs effectiveness in the Korean population by comparing tumor responses. Participants will receive camrelizumab combined with pemetrexed and carboplatin as first-line treatment. Camrelizumab 200 mg is given intravenously on Day 1 of each 3-week cycle for at least 8 cycles 24 weeks. Pemetrexed and carboplatin are also administered intravenously on Day 1 of each cycle, with carboplatin given for 4-6 cycles. This treatment plan aims to study the overall tumor response and progression. Throughout the study, participants undergo tumor assessments using RECIST criteria at regular intervals to measure the best overall response. Additional outcomes include progression-free survival, overall survival, objective response rate, and disease control rate over various time points. Safety and lab tests are performed before treatment, and participants are monitored through the treatment period and up to 6 months after the last visit, with an expected survival of at least 3 months.